Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859978 | 0.94 | L3MBTL1 (0.37) | L3MBTL1LMNATDP1MAPTCYP2C19 | |
| SCHEMBL374291 | 0.90 | LMNA (0.46) | L3MBTL1LMNATDP1MAPTKDM4E | |
| SCHEMBL1870865 | 0.86 | GAA (0.32) | L3MBTL1LMNAGAA | |
| SCHEMBL6955217 | 0.84 | LMNA (0.42) | L3MBTL1LMNATDP1MAPTKDM4E | |
| SCHEMBL4444063 | 0.81 | SLC6A3 (0.33) | — | |
| SCHEMBL13955722 | 0.78 | LMNA (0.50) | L3MBTL1LMNATDP1MAPTKDM4E | |
| SCHEMBL15604555 | 0.77 | NOS2 (0.36) | L3MBTL1LMNAGAA | |
| SCHEMBL25246024 | 0.76 | TDP1 (0.52) | L3MBTL1LMNATDP1MAPTKDM4E | |
| SCHEMBL1538500 | 0.76 | TDP1 (0.52) | L3MBTL1LMNATDP1MAPTKDM4E | |
| SCHEMBL21794157 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566538-B1 | Preparation of 5-(aryloxymethyl)-g-butyrolactone derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-6541647-B2 | Active materials; drugs; antiinflammatory agents; antiallergens | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1094805-A4 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6433197-B1 | REACTING ARYLHYDROXY COMPOUND AND AN EPOXY COMPOUND TO FORM AN EPOXY-ARYL ETHER; REACTING EPOXY-ARYL ETHER WITH ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; REDUCING TO PROVIDE HYDROXY-SUBSTITUTED TETRAHYDROFURAN | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020035278-A1 | Methods for synthesis of substituted tetrahydrofuran compound | MILLENNIUM PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6310221-B1 | PREPARING A 4-FLUOROPHENOXYMETHYL-(HYDROXY)-TETRAHYDROFURAN BY REACTING 4-FLUOROPHENOL AND AN EPOXY COMPOUND; REACTING THE EPOXY-PHENYL ETHER WITH AN ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; AND REDUCING THE LACTONE | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | disclosed |
| US-6306895-B1 | PREPARATION OF CYCLIC OXYGEN COMPOUNDS, INCLUDING 2,5-DISUBSTITUTED TETAHYDROFURANS, 2,6-DISUBSTITUTED TETRAHYDROPYRANS, 2,7-DISUBSTITUTED OXEPANES AND 2,8-OXOCANES. THE INVENTION ALSO PROVIDES NEW CYCLIC OXYGEN COMPOUNDS AND | MILLENIUM PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| CN-1313857-A | Process for the synthesis of substituted tetrahydrofuran compounds | LEUKOSITE INC (US) | 2001-09-19 | — | — | CN | disclosed |
| EP-1102759-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1094805-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001381-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001683-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035278-A1 | Methods for synthesis of substituted tetrahydrofuran compound | DHFR, CYP3A4, CYP3A5 | L3MBTL1 4740/4885LMNA 2041/4885TDP1 3624/4885 |
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | OXER1, COX6C, MT-CO2 | L3MBTL1 4653/4885LMNA 3957/4885TDP1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.